Source author record

Junjun Mao

Junjun Mao appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Catalog footprint

What is connected

1works
1topics
4close collaborators

Actions

Connect this record

Log in to claim

Research graph

See the researcher in context

Open full explorer

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

1 published item(s)

preprint2021arXiv

Time-dependent Clearance of Cyclosporine in Adult Renal Transplant Recipients: A Population Pharmacokinetic Perspective

Aim The pharmacokinetic (PK) properties of cyclosporine (CsA) in renal transplant recipients are patient- and time-dependent. Knowledge of this time-related variability is necessary to maintain or achieve CsA target exposure. Here, we aimed to identify factors explaining variabilities in CsA PK properties and characterise time-dependent clearance (CL/F) by performing a comprehensive analysis of CsA PK factors using population PK (popPK) modelling of long-term follow-up data from our institution. Methods In total, 3,674 whole-blood CsA concentrations from 183 patients who underwent initial renal transplantation were analysed using nonlinear mixed-effects modelling. The effects of potential covariates were selected according to a previous report and well-accepted theoretical mechanisms. Model-informed individualised therapeutic regimens were also conducted. Results A two-compartment model adequately described the data and the estimated mean CsA CL/F was 32.6 L h-1 (5%). Allometrically scaled body size, haematocrit (HCT) level, CGC haplotype carrier status, and postoperative time may contribute to CsA PK variability. The CsA bioavailability in patients receiving a prednisolone dose (PD) of 80 mg was 20.6% lower than that in patients receiving 20 mg. A significant decrease (52.6%) in CL/F was observed as the HCT increased from 10.5% to 60.5%. The CL/F of the non-CGC haplotype carrier was 14.4% lower than that of the CGC haplotype carrier at 3 months post operation. CsA dose adjustments should be considered in different postoperative periods. Conclusions By monitoring body size, HCT, PD, and CGC haplotype, changes in CsA CL/F over time could be predicted. Such information could be used to optimise CsA therapy.